secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eton Pharmaceuticals, Inc. (ETON)
CIK:        0001710340
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0001437749-25-025438
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eton Q2 product sales $18.9M (+108% YoY); non-GAAP EPS $0.03; raises revenue run-rate guidance
--------------------------------------------------------------------------------

- Q2 product sales $18.9M, up 108% YoY; GAAP EPS $(0.10), non-GAAP EPS $0.03.
- Adjusted EBITDA $3.1M vs ($1.6M) prior year; adjusted gross margin improved to 75%.
- Launched KHINDIVI (hydrocortisone oral solution) in June; INCRELEX reached 100 active patients ahead of year-end guidance.
- Company projects $80M annual revenue run rate in Q3, one quarter ahead of prior outlook.
- ET-600 NDA accepted with PDUFA date Feb 25, 2026; second patent granted.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1710340/000143774925025438/0001437749-25-025438-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1710340/000143774925025438/eton20250802_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-025438

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer